Interviewed Thought Leaders Expect Dalcetrapib and Anacetrapib to Deliver Improvements to Mortality and Cardiovascular Morbidity over Zetia, the Sales-Leading Statin Add-on/Alternative Agent for Dyslipidemia
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. primary care physicians (PCPs) and managed care organization (MCO) pharmacy directors agree that improved mortality and morbidity are two of the attributes that most influence their decisions regarding prescribing and formulary status determinations, respectively, in statin add-on/alternative therapies for the treatment of dyslipidemia. Clinical data and the opinions of interviewed thought leaders indicate that Roche/Japan Tobacco's dalcetrapib and Merck's anacetrapib will have advantages on these attributes over Merck's Zetia, the sales-leading agent for statin add-on/alternative therapies for dyslipidemia.
Decision Resources' analysis of the dyslipidemia drug market also finds that surveyed U.S. PCPs indicate that they would prescribe dalcetrapib to 7 percent of their dyslipidemia patients who are already receiving drug therapy. Decision Resources forecasts that dalcetrapib will earn a 3.5 percent patient share in the U.S. dyslipidemia drug market by 2020, owing to its potent lipid-modifying effects and potentially impressive outcomes data.
Currently, Zetia has earned Decision Resources proprietary clinical gold standard status for the indication, owing to its strongest clinical profile among key marketed statin add-on/alternative therapies that treat dyslipidemia.
“However, following its launch for the indication in 2014, dalcetrapib will displace Zetia and will earn proprietary clinical gold-standard status for dyslipidemia (statin add-on/alternative therapies) in 2015, owing to its competitive advantages in efficacy attributes,” said Decision Resources Analyst Pam Narang, Ph.D.
According to insights from surveyed U.S. PCPs and MCO pharmacy directors, improved mortality and cardiovascular morbidity are two of the greatest unmet needs in statin add-on/alternative therapies for the treatment of dyslipidemia. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi/Isis Pharmaceutical's Kynamro, anacetrapib and dalcetrapib have demonstrated the potential to partially fulfill this unmet need.
With sales of more than $29 billion in 2010, dyslipidemia remains one of the world's largest pharmaceutical markets. However, several leading blockbuster brands are nearing the end of their lifecycles and generic erosion will be the major contributor to a $5.9 billion sales decline by 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The much-anticipated arrival of CETP inhibitors will begin in 2014 with the launch of dalcetrapib. Decision Resources expects rapid uptake of dalcetrapib, anacetrapib and Eli Lilly's evacetrapib as add-on therapies, particularly in coronary heart disease (CHD) and CHD risk-equivalent patients, with sales of the CETP inhibitor drug class expected to exceed $5.4 billion in 2020.
Decision Resources' Robust Market Forecast and Opportunities Analysis
Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597